TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive ACS Creates $1 Billion Nationwide Organization, Taking Fiduciary Control From 12 Divisions November 18, 2011
TCL Archive In Brief: UICC Publishes International directory Of Cancer Centers; HSAs Still Worry NCI January 7, 1977
